Mechanism of Azalomycin F5a against Methicillin-Resistant Staphylococcus aureus

To investigate the mechanism of azalomycin F5a against methicillin-resistant Staphylococcus aureus (MRSA), the conductivity of MRSA suspension and the adenylate kinase activity of MRSA culture were determined with the intervention of azalomycin F5a, which were significantly increased compared to those of blank controls. This inferred that azalomycin F5a could lead to the leakage of cellular substances possibly by increasing permeability to kill MRSA. As phospholipid bilayer was mainly responsible for cell-membrane permeability, the interaction between azalomycin F5a and cell-membrane lipids was further researched by determining the anti-MRSA activities of azalomycin F5a combined with cell-membrane lipids extracted from test MRSA or with 1,2-dipalmitoyl-sn-glycero-3-phospho-glycerol (DPPG) for possible molecular targets lying in MRSA cell-membrane. The results indicated that the anti-MRSA activity of azalomycin F5a remarkably decreased when it combined with membrane lipids or DPPG. This indicated that cell-membrane lipids especially DPPG might be important targets of azalomycin F5a against MRSA.

[1]  Daptomycin , 2020, Reactions Weekly.

[2]  Ganjun Yuan,et al.  Mutant Selection Windows of Azalomycin F 5a in Combination with Vitamin K 3 against Methicillin-Resistant Staphylococcus aureus , 2016 .

[3]  H. Mo,et al.  Antibacterial characteristics and mechanisms of ɛ-poly-lysine against Escherichia coli and Staphylococcus aureus , 2014 .

[4]  Ganjun Yuan,et al.  Anti-methicillin-resistant Staphylococcus aureus assay of azalomycin F5a and its derivatives. , 2014, Chinese journal of natural medicines.

[5]  Ganjun Yuan,et al.  The relative configurations of azalomycins F5a, F4a and F3a , 2013 .

[6]  K. Hong,et al.  New Azalomycin F Analogs from Mangrove Streptomyces sp. 211726 with Activity against Microbes and Cancer Cells , 2013, Marine drugs.

[7]  A. Bayer,et al.  Correlation of Cell Membrane Lipid Profiles with Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.

[8]  L. Didone,et al.  Adenylate Kinase Release as a High-Throughput-Screening-Compatible Reporter of Bacterial Lysis for Identification of Antibacterial Agents , 2012, Antimicrobial Agents and Chemotherapy.

[9]  K. Hong,et al.  1H and 13C assignments of two new macrocyclic lactones isolated from Streptomyces sp. 211726 and revised assignments of Azalomycins F3a, F4aand F5a , 2011, Magnetic resonance in chemistry : MRC.

[10]  S. Yang,et al.  Azalomycin F complex is an antifungal substance produced by Streptomyces malaysiensis MJM1968 isolated from agricultural soil , 2010 .

[11]  Y. Dufrêne,et al.  Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. , 2010, Biochimica et biophysica acta.

[12]  J. Hinds,et al.  Insertion of Epicatechin Gallate into the Cytoplasmic Membrane of Methicillin-resistant Staphylococcus aureus Disrupts Penicillin-binding Protein (PBP) 2a-mediated β-Lactam Resistance by Delocalizing PBP2 , 2010, The Journal of Biological Chemistry.

[13]  R. H. Baltz.  Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. , 2009, Current opinion in chemical biology.

[14]  C. Nast,et al.  Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[15]  M. Struelens,et al.  The bacterial envelope as a target for novel anti-MRSA antibiotics. , 2008, Trends in pharmacological sciences.

[16]  F. Tally,et al.  Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. , 2005, The Journal of antimicrobial chemotherapy.

[17]  M. Nair,et al.  Azalomycin F complex from Streptomyces hygroscopicus, MSU/MN-4-75B. , 1995, The Journal of antibiotics.

[18]  S. Iwasaki,et al.  Studies on Macrocyclic Lactone Antibiotics. V. The Structures of Azalomycins F3a and F5a , 1982 .

[19]  K. Hamano,et al.  Isolation of three main components. F3, F4 and F5, from azalomycin F-complex. , 1970, The Journal of antibiotics.

[20]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[21]  S. Sugawara.  Effect of azalomycin F on bacteria. , 1968, The Journal of antibiotics.

[22]  Brad Spellberg,et al.  The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  K. Hiramatsu.  Elucidation of the Mechanism of Antibiotic Resistance Acquisition of Methicillin-Resistant Staphylococcus Aureus (MRSA) and Determination of Its Whole Genome Nucleotide Sequence , 2004 .

[25]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .